InMed Pharmaceuticals (INM) Competitors $2.25 -0.01 (-0.44%) Closing price 04:00 PM EasternExtended Trading$2.19 -0.06 (-2.67%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. MBRX, LIXT, ADAP, CMMB, PULM, HOTH, LSB, ABP, NRSN, and SYBXShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Moleculin Biotech (MBRX), Lixte Biotechnology (LIXT), Adaptimmune Therapeutics (ADAP), Chemomab Therapeutics (CMMB), Pulmatrix (PULM), Hoth Therapeutics (HOTH), LakeShore Biopharma (LSB), Abpro (ABP), NeuroSense Therapeutics (NRSN), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Its Competitors Moleculin Biotech Lixte Biotechnology Adaptimmune Therapeutics Chemomab Therapeutics Pulmatrix Hoth Therapeutics LakeShore Biopharma Abpro NeuroSense Therapeutics Synlogic Moleculin Biotech (NASDAQ:MBRX) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends. Is MBRX or INM more profitable? Moleculin Biotech has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. InMed Pharmaceuticals' return on equity of -107.93% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -1,498.41% -114.47% InMed Pharmaceuticals -168.87%-107.93%-82.97% Which has stronger earnings & valuation, MBRX or INM? InMed Pharmaceuticals has higher revenue and earnings than Moleculin Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$21.76MN/AN/AInMed Pharmaceuticals$4.60M0.98-$7.68M-$12.09-0.19 Does the media favor MBRX or INM? In the previous week, Moleculin Biotech had 2 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 3 mentions for Moleculin Biotech and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 1.87 beat Moleculin Biotech's score of 0.62 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Moleculin Biotech Positive InMed Pharmaceuticals Very Positive Do insiders & institutionals hold more shares of MBRX or INM? 15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 2.1% of Moleculin Biotech shares are held by company insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, MBRX or INM? Moleculin Biotech has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Do analysts rate MBRX or INM? Moleculin Biotech presently has a consensus target price of $4.00, suggesting a potential upside of 558.65%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Moleculin Biotech is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMoleculin Biotech beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.51M$2.51B$5.76B$9.78BDividend YieldN/A1.69%3.95%4.03%P/E Ratio-0.1922.5330.8026.37Price / Sales0.98739.53467.21121.85Price / CashN/A177.7737.7659.36Price / Book0.116.2910.106.62Net Income-$7.68M$32.94M$3.26B$265.42M7 Day Performance1.35%2.27%3.91%3.58%1 Month Performance-14.77%1.06%3.74%0.46%1 Year Performance-72.14%5.65%37.68%19.41% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals1.4077 of 5 stars$2.25-0.4%N/A-70.4%$4.51M$4.60M-0.1910Positive NewsMBRXMoleculin Biotech2.8752 of 5 stars$0.60-1.2%$4.00+566.7%-78.6%$18.17MN/A0.0020Analyst ForecastGap DownLIXTLixte Biotechnology0.177 of 5 stars$3.95+3.4%N/A+72.0%$18.01MN/A-3.064Gap DownADAPAdaptimmune Therapeutics1.9494 of 5 stars$0.07-2.0%$1.35+1,870.4%-95.6%$17.94M$65.09M-0.10490CMMBChemomab Therapeutics3.2579 of 5 stars$0.94+0.2%$8.50+802.3%-46.2%$17.77MN/A-1.6020News CoverageAnalyst ForecastPULMPulmatrix0.8671 of 5 stars$4.79+1.7%N/A+144.0%$17.42M$369K-2.2020News CoveragePositive NewsHOTHHoth Therapeutics2.788 of 5 stars$1.28-1.2%$4.00+213.7%+60.4%$16.91MN/A-1.194Positive NewsLSBLakeShore Biopharma1.5248 of 5 stars$0.81-1.0%N/A-82.1%$16.87M$85.67M0.00773Positive NewsABPAbproN/A$0.28+2.2%$4.00+1,349.8%N/A$16.77M$180K0.0015Positive NewsNRSNNeuroSense Therapeutics2.3184 of 5 stars$1.23-2.0%$14.00+1,042.9%+45.3%$16.75MN/A-2.2710SYBXSynlogic1.1282 of 5 stars$1.43flatN/A+0.7%$16.73MN/A-0.5780Positive News Related Companies and Tools Related Companies MBRX Alternatives LIXT Alternatives ADAP Alternatives CMMB Alternatives PULM Alternatives HOTH Alternatives LSB Alternatives ABP Alternatives NRSN Alternatives SYBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access